14.37  0.17 (1.2%)		10-14 16:00
Open: 14.2 High: 14.39 Volume: 984,937		Pre. Close: 14.2 Low: 14.055 Market Cap: 1,387(M)

Short term
Mid term
Targets	6-month :	17.98	1-year :	19.12
Resists	First :	15.39	Second :	16.37
Pivot price	14.78
Supports	First :	13.82	Second :	11.5
MAs	MA(5) :	14.19	MA(20) :	15.08
	MA(100) :	12.21	MA(250) :	10.67
MACD	MACD :	-0.2	Signal :	0
%K %D	K(14,3) :	16.5	D(3) :	9.6
RSI	RSI(14): 43
52-week	High :	16.65	Low :	6.38

Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ AVDL ] has closed above bottom band by 29.5%. Bollinger Bands are 0.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	14.41 - 14.48	14.48 - 14.55
Low:	13.88 - 13.96	13.96 - 14.04
Close:	14.24 - 14.37	14.37 - 14.49

Avadel Pharmaceuticals plc operates as a biopharmaceutical company in the United States. Its lead product candidate is FT218, a formulation of sodium oxybate, which is in a Phase 3 clinical trial for the treatment of excessive daytime sleepiness and cataplexy in adults with narcolepsy. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals plc in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.

Mon, 13 Oct 2025
Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Mon, 13 Oct 2025
161,600 Options Granted — Avadel awards 10-year options to 7 new employees with 4-year vesting - Stock Titan

Sun, 05 Oct 2025
Analysts Expect Avadel Pharmaceuticals plc (NASDAQ:AVDL) To Breakeven Soon - Yahoo Finance

Tue, 30 Sep 2025
Avadel: Mispriced Leader In Once-Nightly Sleep Therapies - Seeking Alpha

Sun, 28 Sep 2025
Avadel Pharmaceuticals PLC. (NASDAQ:AVDL) Given Consensus Rating of "Buy" by Analysts - MarketBeat

Wed, 24 Sep 2025
Why The Story Around Avadel Pharmaceuticals Is Evolving After Recent Analyst and Market Updates - Sahm

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Underperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Underperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Underperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Shares Out	97 (M)
Shares Float	81 (M)
Held by Insiders	4.8 (%)
Held by Institutions	86 (%)
Shares Short	9,930 (K)
Shares Short P.Month	10,480 (K)

EPS	-0.02
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	0.93
Profit Margin	-1.4 %
Operating Margin	13 %
Return on Assets (ttm)	-1.2 %
Return on Equity (ttm)	-3.7 %
Qtrly Rev. Growth	64.1 %
Gross Profit (p.s.)	2.04
Sales Per Share	2.27
EBITDA (p.s.)	0
Qtrly Earnings Growth	0 %
Operating Cash Flow	5 (M)
Levered Free Cash Flow	5 (M)

PE Ratio	-718.5
PEG Ratio	0
Price to Book value	15.28
Price to Sales	6.31
Price to Cash Flow	256.02

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.